GSK touts expectations for 14 late-stage pipeline drugs

GlaxoSmithKline ($GSK) rolled out its late-stage drug prospects today, putting its best foot forward with a pair of drugs aimed at cancer and heart disease. Altogether, the pharma giant says it expects to post pivotal data on 14 therapeutics in the next two years. Report

Read more on